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In this study, we have implemented a new quality control (QC) parameter for peptide profiling
based on isotopic distributions. This QC parameter is an objective measure and facilitates
automatic sorting of large numbers of peptide spectra. Peptides in human serum samples were
enriched using reversed-phase C18-functionalized magnetic beads using a high-throughput
robotic platform. High-resolution MALDI-TOF and ultrahigh resolution MALDI-FTICR mass
spectra were obtained and a workflow was developed for automated analysis and evaluation
of these profiles. To this end, the isotopic distributions of multiple peptides were quantified
from both MALDI-TOF and MALDI-FTICR spectra. Odd peptide isotope distributions in TOF
spectra could be rationalized from ultrahigh resolution FTICR spectra that showed overlap of
different peptides. The comparison of isotope patterns with estimated polyaveragine distri-
butions was used to calculate a QC value for each single mass spectrum. Sorting these QC
values enabled the best MALDI spectrum to be selected from replicate spots. Moreover, using
this approach spectra containing high intensities of polymers or other contaminants and
lacking peptides of interest can be efficiently removed from a clinical dataset. In general, this
method simplifies the exclusion of low quality spectra from further statistical analysis. (J Am
Soc Mass Spectrom 2010, 21, 1515–1525) © 2010 American Society for Mass SpectrometryIn the past decade, discovery studies in clinicalproteomics have evolved synergistically with thetechnological progress made in mass spectrometry
(MS). The growth in the field of MS-based proteomics
[1, 2] has been driven by the introduction of new
identification techniques [3, 4] and improvements in the
resolution, mass accuracy, robustness, and dynamic
range of modern mass analyzers [5–8]. From the early
days, serum peptide- and protein profiling has played a
major role in clinical studies for biomarker discovery,
aiming at identifying differences in peptide- and pro-
tein levels in serum of healthy and diseased individuals
[9–13]. Peptide and protein patterns can change as a
result of disease and are thus helpful in both early
detection and monitoring the development of the dis-
ease. However, serum is a very complex mixture of
biomolecules and, therefore, requires appropriate sam-
ple workup. In addition to the complexity, the peptide
and protein profiles of serum are usually dominated by
highly abundant species (the tip of the iceberg) [14].
Different strategies have been followed to reduce the
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doi:10.1016/j.jasms.2010.05.004biological complexity of human serum samples and
multiple methods and technologies have been devel-
oped for the purpose of sample workup [15–19]. The
combination of protein and peptide extraction using
functionalized magnetic beads with matrix-assisted la-
ser desorption/ionization (MALDI) MS has been
widely used for profiling studies [20–22]. One of the
advantages of this approach is that automation of both
solid-phase extraction (SPE) and MS allows high-
throughput screening. Also, for each serum sample,
fresh disposable magnetic beads are used, thus avoid-
ing carry-over that may occur when other techniques
such as liquid chromatography (LC) are used. More-
over, magnetic beads with a different functionality
allow protein- and peptide enrichment based on differ-
ent chemical-physical interactions, thus broadening the
range of components covered.
Several studies have focused in detail on sources of
variance in profiling experiments and the necessity of
standardization in sample collection and preparation
has been demonstrated [23–25]. Robotic liquid handling
has the advantage of better reproducibility of the SPE
and a greatly increased throughput. Robotic platforms
enable a fully automated use of magnetic beads and
ensure the control of each step in the extraction protocol
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of MALDI MS allows the analysis of thousands of
samples in a realistic time period. The application of
statistical analysis for the evaluation of the high number
of data generated using this strategy, finally enables a
more confident identification of possible biomarkers.
In profiling studies, the most commonly used mass
analysis in combination with MALDI is time-of-flight
mass spectrometry (TOF-MS) [29–31]. Following the
current developments in high-resolution mass spec-
trometry, MALDI coupled with Fourier transform ion
cyclotron resonance (FTICR-MS) has been applied for
the same purpose [32, 33]. The high-resolution and low
or even sub-ppm mass measurement errors result in
more confident peptide and protein assignments. In this
study, we compared peptide profiles using the two
MS-platforms indicated above, i.e., MALDI-TOF and
MALDI-FTICR. With respect to large-scale mass spec-
trometric proteomic or peptidomic profiling experi-
ments, the quality control (QC) of both the workflow
and the data yielded is an arduous task. Variations can
occur pre-analytically (blood collection, clotting time,
storage conditions), in the analytical workflow, and in
the data acquisition (MS experiments). The human eye
is extremely good at differentiating multiple pictures,
e.g., peptide profiles. However, the visual inspection of
all acquired spectra would be time-consuming and
subjective. For this reason, various QC procedures and
tools have been developed that allow (automated) eval-
uation of peptide- and protein MS profiles [34–38].
Generally, the signal to noise ratio and/or the threshold
of the noise level are taken into account, whereas in
MALDI MS protein and peptide profiling the reproduc-
ibility of the signal intensity is rigorously evaluated [39,
40]. The use of a highly robust protocol including
replicate measurements for each sample allows further
standardization. The evaluation of noise levels of dif-
ferent datasets (e.g., different MALDI plates) is more
cumbersome and prone to bias. In this study, we
describe a novel QC approach for the automatic selec-
tion of mass spectra, based on peptide isotopic distri-
butions. To this end, the previously used model amino
acid averagine was used to carry out detailed compar-
isons [41]. A recently developed integration method
was used to obtain intensity values for each isotope
signal within a given distribution. We will show that
this QC parameter can clearly discriminate good and
poor peptide spectra.
Materials and Methods
Blood Collection and Serum Handling
Blood samples were collected from patients and healthy
volunteers by antecubital venipuncture while the per-
son was seated. Informed consent was obtained from all
patients, and the Leiden University Medical Center
(LUMC) Medical Ethical Committee approved the stud-
ies. All clinical studies were carried out under supervi-sion of the Department of Surgery at the LUMC. It is
outside the scope of this paper to give a detailed
description of the various patient cohorts. Subsets of the
data will be reported elsewhere.
Within 1 h after collection of blood in a 10 mL BD
vacutainer tube (containing a clot activator and a gel for
serum separation) the sample was centrifuged for 10
min at 1500  g. The serum was then transferred to a 1
mL polypropylene cryovial, frozen, and stored at
80 °C. Each cryovial was thawed only once and di-
vided over eight 50 L Matrix 2D barcoded storage
tubes (Thermo Fisher Scientific Inc., Hudson, NH, USA)
using an 8-channel Hamilton pipetting robot. These
tubes were then distributed over eight different 96-
sample matrix latch racks, thus yielding eight identical
Matrix racks containing 96 different serum samples.
These racks were frozen again at 80 °C and a rack
was thawed only once for the automated peptide
capture procedure. The sample thawing time, i.e., the
time between taking a rack out of the freezer and the
starting time of the peptide isolation procedure (next
section), was between 30 and 60 min for all serum
samples. This high degree of standardization in sample
handling and sample thawing-time in combination with
the use of the 96-channel pipetting robot ensured iden-
tical (robust) and simultaneous treatment of all serum
samples in the peptide isolation procedure.
High-Throughput Peptide Isolation with RPC18
Dynabeads and MALDI Spotting
The isolation of peptides from human serum was per-
formed using reversed-phase C18-functionalized mag-
netic beads [11, 26, 27]. For each sample, a fresh
suspension of paramagnetic monodisperse beads was
used and all 96 serum samples in one Matrix rack were
incubated with the same lot-number of beads. In this
study 10 L of commercially available RPC18 Dyna-
beads (Invitrogen, Carlsbad, CA, USA) was used for the
analysis of 5 L of undiluted human serum. The acti-
vation, wash, and desorption steps of the RPC18 beads
were based on the manufacturer’s protocol; however,
the protocol was adjusted to enable an optimal imple-
mentation on a 96-channel Hamilton STARplus pipet-
ting robot (Hamilton, Bonaduz, Switzerland). In short, a
plate containing 96 magnets was designed and built
in-house to accommodate a 96-well PCR microtiter
plate (MTP) and to allow for optimal settlement of the
magnetic beads at the bottom of each well. Further-
more, it was found that additional activation steps were
needed, since automated pipetting does not allow the
removal of all liquid from the pulled-down magnetic
beads. Thus, for optimal removal of preservatives dur-
ing the activation step the RPC18 beads were washed
three times with 50 L of water. For similar reasons,
after binding of the peptides to the RPC18 beads three
wash steps with 50 L of a 0.1% trifluoroacetic acid
solution were carried out. Finally, the eluates obtained
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acetonitrile solution) were transferred into a 96-well
plate and mixed with stabilization buffer. A portion of
these eluates (2 L) was used for MALDI-spotting
while the remainder was frozen and stored at 80 °C
for future analysis.
The 96-channel Hamilton STARplus pipetting robot
was used for mixing of sample eluates with MALDI-
matrix, followed by spotting on a MALDI target plate.
To this end, 2 L of the stabilized eluate was transferred
into a fresh 384-well MTP and mixed with 10 L of
-cyano-4-hydroxycinnamic acid (0.3 g/L in ethanol:
acetone 2:1). Four MALDI spots of each eluate were
obtained after quadruplicate spotting on a MALDI
AnchorChip (600 m; Bruker Daltonics, Bremen, Ger-
many) using 1 L of the eluate/matrix mixture for each
spot.
MALDI-TOF and -TOF/TOF Mass Spectrometry
After MALDI spotting, the target plate was immedi-
ately stored in a storage chamber (RT, 5% oxygen, 95%
nitrogen), until transfer into the MALDI-TOF instru-
ment by a CRS F3 robotic arm (Thermo Fisher Scientific
Inc., Marietta, OH, USA), as a fully automated plate
loader [42]. In this way, all MALDI-TOF measurements
were carried out within 12 h after spotting on the
96-channel robot. All MALDI-TOF experiments were
performed on an UltraFlex III (Bruker Daltonics) oper-
ating in positive reflectron mode in the m/z range of
600–4000. The spectra were acquired using FlexControl
software ver. 3.0 (Bruker Daltonics) with identical data
acquisition parameters. A SmartBeam 200 Hz solid-
state laser, set at a frequency of 100 Hz, was used for
ionization. A profile, or summed spectrum, was ob-
tained for each MALDI-spot by adding 20 spectra of 60
laser shots each at different rasters. FlexControl soft-
ware decided on-the-fly whether or not a scan was
used for the summed spectrum. To this end, a resolu-
tion higher than 2000 was required. Peaks were de-
tected using the SNAP centroid peak detection algo-
rithm with signal-to-noise threshold of 1 and a
“TopHat” baseline subtraction. All mass scans not fit-
ting these criteria were excluded. The measurement of a
MALDI spot was finished when 1200 laser shots had
been summed in one profile. The MALDI-TOF spectra
were measured from m/z 600 to 4000 and externally
calibrated using a commercially available peptide mix
(Bruker Daltonics). FlexAnalysis Software 3.0 (Bruker
Daltonics) was used for visualization and initial data
processing.
For identification, the LIFT-TOF/TOF spectra were
recorded on the same Bruker Ultraflex III TOF/TOF
mass spectrometer. No additional collision gas was
applied. Precursor ions were accelerated to 8 kV and
selected in a timed ion gate. The fragments were further
accelerated by 19 kV in the LIFT cell, and their masses
were analyzed after the ion reflector passage.Peak Alignment in MALDI-TOF Serum
Peptide Profiles
The workflow for processing peptide profiles is de-
picted in Figure 1. After external calibration using a
commercially available peptide mix, the maximum ob-
served mass shift in the 384 spectra varied from0.1 Da
at m/z 1500 to 0.2 Da at m/z 4000. Before carrying out the
alignment a baseline subtraction of all spectra was
performed. To allow the alignment of all 384 spectra
from one MALDI target plate at least three peptides at
different m/z values were needed for internal calibra-
tion. To compensate for the possible absence of one or
two peptides in a spectrum, the following five peptides
were selected based on a manual inspection of a few
spectra, namely m/z 1465.8, 1778.1, 1865.2, 2602.5, and
2931.5, with a tolerance window of 100 ppm for the m/z
1465.8 peak increasing up to 300 ppm for the highest
m/z value (FlexAnalysis 3.0).
Determination of Peak Intensities Using Xtractor
All MALDI-TOF and the MALDI-FTICR spectra were
exported as DAT (.dat) and XY (.xy) files, respectively.
In both formats (ASCII), all m/z values with correspond-
ing intensities (i.e., data points) were reported. The
simple Xtractor tool was used to determine the intensity
of each user-defined peak [43]. To this end, a certain m/z
window was defined for each peak included in a
so-called reference file, thus allowing Xtractor to sum
all the intensities of the data points within the defined
bin. The bin size for all peaks in the MALDI-TOF
spectra was fixed at 0.49 Da, the bin size for the peaks
Figure 1. Overview of three sequential processing methods for
the generation and evaluation of human serum peptide profiles.
The novel QC method reported here is carried out in the third
step.
1518 NICOLARDI ET AL. J Am Soc Mass Spectrom 2010, 21, 1515–1525in the MALDI-FTICR spectra varied from 0.02 Da at
m/z 1465.8 to 0.08 Da at m/z 2931.5. In this way, single
intensity values for each isotopic peak within any
isotope distribution were obtained. Importantly, Xtrac-
tor generates uniform data (peak) arrays regardless of
spectra content (Xtractor is an open source tool and can
be found at www.ms-utils.org/Xtractor).
Calculation of Peak Intensities in Peptide Isotope
Distributions
The observed peptide isotopic distributions were com-
pared with those obtained from the polyaveragine
model as explained in Results and Discussion section.
The theoretical isotopic distribution of a polyaveragine
peptide was calculated using chemcalc (www.chemcalc.
org). The elemental composition used for the calcula-
tion of peak intensities of each individual isotope re-
flected a singly protonated polyaveragine peptide mol-
ecule with integer numbers for all indices of the atoms
C, H, N, O, and S. In a similar way, the theoretical
isotopic distribution of the peptide at m/z 1465.8 was
calculated after identification of this peptide using
MALDI-TOF/TOF. Note that each individual isotope
within a distribution was considered as one single peak,
as described earlier by Rockwood et al. [44] Thus, by
using the jcamp file from chemcalc, all calculated inten-
sities within the isotopic fine structure of the second
and third peak were summed to two individual values
only.
MALDI-FTICR Mass Spectrometry
All MALDI-FTICR experiments were carried out on a
Bruker Daltonics apex-ultra 9.4 tesla FTICR mass spec-
trometer. This instrument was equipped an Apollo II
dual ion source, two ion funnels, a selection quadrupole
in the front-end, and an Infinity ICR cell. For the
purpose of comparing FTICR-measurements with re-
sults obtained from the TOF, manual MALDI-spotting
was carried out from a frozen 96-well eluate plate. After
thawing the RPC18 eluates at room-temperature, 2 L
of each eluate was transferred into a 384-well plate and
mixed with 10 L of -cyano-4-hydroxycinnamic acid
(0.3 g/L in ethanol:acetone 2:1). Finally, 1 L of this
mixture was manually spotted on a MALDI Anchor-
Chip (600 m) in duplicate using a standard Gilson P2
pipette. In this way, 192 spots of 96 different samples
were obtained. These spots were measured on the
FTICR using a SmartBeam 200 Hz solid-state laser,
operated a frequency of 100 Hz. The irradiation spot
size was 200 m. The ions generated from 50 laser
shots were accumulated in the hexapole and then
transferred through the quadrupole to the collision cell.
This process was repeated eight times per example on
different raster spots. The 450 laser shots accumulated
in the collision cell were then transferred to the ICR cell
for mass analysis. The quadrupole was set to an m/z of400 and RF amplitude of 3000 Vp-p. Each spectrum was
generated by accumulation of eight scans with 512 K
data points. All data were acquired using the Bruker
ApexControl software and evaluated using Bruker
DataAnalysis software.
Results and Discussion
Peptide Isotope Distributions in MALDI-TOF
Spectra
The workflow for sample, profile, and data processing
is depicted in Figure 1. One of the aims of this study
was to demonstrate the use of peptide isotopic distri-
butions of peptides for quality control parameter. For
illustration, the isotopic patterns of the five ubiquitous
peptides used for alignment are shown in Figure 2.
While the selection of these five peptides was an
arbitrary process, no software is available that yields a
better result without the need of user-defined input
parameters. One of these peptides was identified,
namely m/z 1465.8, as a fragment of fibrinogen -chain
(P02671, peptide DSGEGDFLAEGGGVR). Previous re-
ports corroborate this identification [45]. Using the
elemental composition of this peptide the theoretical
isotopic distribution was calculated (see the Materials
and Methods section). It should be emphasized, how-
ever, that identification of the peptides is not necessary
for the evaluation of isotopic distributions, but clearly
becomes important at the stage a biomarker candidate
has been detected. Different strategies, followed by
adjustments, have been proposed for the estimation of
isotopic distributions of unidentified peptides [36, 46,
47]. In this study, we used the “averagine” model,
proposed by Senko et al. to construct peptides from a
hypothetical average amino acid [41]. This is sufficient
for the estimation of isotopic distribution of unknown
peptides since we are not searching for the best fit, but
only need to discriminate between peptide and non-
peptide (e.g., polymer, matrix cluster) distributions. The
estimated values of the five peptides are depicted in
Figure 2. These are obtained by first transferring a
peptide m/z value into a neutral mass (i.e., [m/z value–
proton–water]), then dividing this number by the exact
mass of averagine (i.e., 111.0543 Da), and multiplying
the result with the indices of the molecular formula of
averagine (i.e., C4.9384H7.7583N1.3577O1.4773S0.0417). Finally,
one “water-molecule” and a proton are added to create
the corresponding “polyaveragine” molecular formula
and m/z value. Due to rounding of the indices, the m/z
values of the observed peptide and the corresponding
polyaveragine are not identical. It is clear from Figure 2
that the isotopic patterns of the five peptides used for
alignment were in good agreement with the polyaver-
agine distributions. A quantitative evaluation of these
isotope distributions will be given in the next section.
Differences with estimated distributions may be indic-
ative of the presence of peptides that contain post-
tide
1519J Am Soc Mass Spectrom 2010, 21, 1515–1525 QUALITY CONTROL BASED ON ISOTOPIC DISTRIBUTIONS FOR PROFILINGtranslational modifications (PTMs) or metal cations, or
may point at overlapping peptides. Two examples of
the latter cause of aberrant isotopic distributions are
revealed in Figure 3a. Here, the isotope distributions
of two peptides present in some of the MALDI-TOF
profiles did not match those of the corresponding
polyaveragine peptides. Subsequent high-resolution
FTICR mass analysis of the same m/z values clearly
showed overlap of two different peptides. Further
analysis showed that the weighted sum of two esti-
mated polyaveragine distributions (with a mass dif-
ference of one Da) matched the distributions ob-
served in the TOF spectra. Differences with estimated
distributions can be also indicative of sample con-
tamination, such as polymers [48]. An example of
MALDI-FTICR spectrum that contains polymer Tinuvin-
622 is shown in Figure 3b. The comparison of the
isotopic distribution of the polymer at m/z  1732
with that estimated from a polyaveragine peptide
with an m/z of 1787 clearly shows that the species at
Figure 2. (a) MALDI-TOF peptide profile obta
RPC18-functionalized magnetic beads. (b) Obser
alignment of all serum peptide profiles. The ho
calculated values of the corresponding polyaver
value for each individual mass spectrum. First, t
Xtractor. Then, after normalization, the observed
the polyaveragine peptide. For a more accurat
variance is taken into account. Finally, the sum o
represents the QC value of the MALDI-TOF pepm/z  1732 is not a peptide.Quality Control Based on Peptide Isotope
Distributions
The intensities of the observed peaks in each peptide
isotope distribution were determined using Xtractor
(see the Materials and Methods section). As an example,
for the peptide at m/z 1865.22 the intensity of the
monoisotopic was determined as the sum of all mea-
sured values at m/z 1865.22  0.49, the intensity of the
second isotope was determined as the sum of all
measured values at m/z 1866.22  0.49, and so forth
(Figure 2). The window of 0.49 Da was chosen to ensure
total quantification of each isotope. This window of 0.49
Da does not reflect the actual peak width, i.e., the
resolution of the peptides in the MALDI-TOF spectra
varied from about 7000 atm/z 1465.8 and about 10,000 at
m/z 2931.5. It should be noted that the density of data
points decreases with increasing m/z values in a TOF
spectrum. As a result, the number of data points within
each bin differs between different peptides. However,
from human serum after sample workup using
sotopic distributions of five peptides chosen for
tal lines at the top of the peaks represent the
peptides. (c) Profile processing results in a QC
tensity of each isotope peak is determined using
nsities are compared with those estimated from
ermination of the deviation, the random noise
obtained deviations for all considered peptides
profile in (a).ined
ved i
rizon
agine
he in
inte
e det
f thuswithin one peptide isotopic pattern, the number of data
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for the five peptides considered here.
Three intensity values were obtained for all five
peptides previously discussed in the spectral alignment
part using the Xtractor tool. All isotope intensities were
then normalized using the sum of the first three inten-
sities within the distribution. These intensities were
compared with the corresponding abundances in a
Figure 3. (a) Examples of deviations from the polyaveragine
model due to overlap of different peptides. Left panel: enlarged
part of a MALDI-TOF human serum peptide profile showing odd
isotopic distributions. Middle panel: calculated isotope distribu-
tions of the corresponding polyaveragine peptides. Right panel:
enlarged part of the MALDI-FTICR mass spectrum of the same
spot reveals the presence of overlapping peptides 1 and 2 that
cause the odd isotopic distribution in the MALDI-TOF spectra,
and overlapping peptides 3 and 4. (b) Example of deviation from
the polyaveragine model due to different peak identity. A
MALDI-FTICR spectrum dominated by polymers of tinuvin-622
(poly-(N--hydroxyethyl-2,2,6,6-tetramethyl-4-hydroxy-piperidinyl
succinate). The enlarged part shows the isotopic distribution of the
polymer m/z 1732 and the isotopic distribution calculated from a
polyaveragine peptide with m/z 1787 (horizontal bars).polyaveragine isotopic distribution, as previously de-scribed by Palmblad et al. [49]. Here, the total signal
variance is taken into account in the parameter m
2 . In
the aforementioned study, carried out using electros-
pray ionization (ESI) FTICR-MS, m
2 contained two
terms, namely, experimental signal variance, which was
approximately proportional to signal strength, and
noise variance, which was constant. In MALDI spectra;
however, every single laser shot yields a different
amount of ions. As a result, the noise levels are not
constant. In general, in the MALDI-TOF experiments
performed in this study the noise variance decreased at
increasing m/z values, whereas the opposite was true
for the MALDI-FTICR spectra. For the purpose of
biomarker discovery and subsequent validation a de-
tailed evaluation of noise variance is pivotal. In this
respect, various studies have been reported to deter-
mine sources of variance and to provide tools for
quantification [14, 25, 31, 34]. The aim of this work is the
development of a new tool for evaluation of spectral
quality to improve future biomarker discovery studies.
To this end, for further calculations the total signal
variance m
2 was estimated as follows. For one single
MALDI target plate the noise levels in TOF- and FTICR
profiles were determined for each of the five considered
peptides as an average from 10 different samples (sum-
marized in Table 1). Thus, m
2 was considered constant
at a specific m/z value for each sample on one MALDI
target plate. Based on visual inspection of the spectrum,
an “empty” m/z region was selected for each peptide
used for alignment to calculate a corresponding m
2
value. Using these m
2 values the deviations between
estimated and observed isotopic distributions were
determined and summed to one single QC value for
each spectrum according to eq 1:
(QC-value)2
p1
p

m1
M Im∗ (est.) Im∗ (obs.)2
m
2
in which P and M are the number of peptides and
isotopes considered per peptide, respectively; Im
∗ est.
and Im
∗ obs. are the intensities of the estimated and
observed isotopic peaks normalized for the sum of the
intensities of the first three isotopic peaks in the corre-
sponding isotopic distributions; the m
2 value is the
random variance noise calculated in a small set of
analyzed spectra.
As an example, the QC values of 384 mass spectra
(quadruplicate spots of 96 different serum samples on
one MALDI target plate) are depicted in Figure 4. Note
that a low QC value corresponds with a high quality
spectrum. For most samples with a high quality profile,
a similar QC value was observed for the four replicates,
as exemplified for S21 in Figure 4. From this it was be
concluded that MALDI-spotting followed by mass anal-
ysis showed good repeatability. QC based on isotopic
distribution is a powerful tool for the evaluation of
samples that yield low quality spectra. In some cases,
only one out of four spectra was poor, as exemplified
for S83, in other cases three out of four replicates were
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1521J Am Soc Mass Spectrom 2010, 21, 1515–1525 QUALITY CONTROL BASED ON ISOTOPIC DISTRIBUTIONS FOR PROFILINGpoor (e.g., S4 and S49). For this reason it is proposed to
select the “best” spectrum of each sample for statistical
analysis, i.e., with the lowest QC value. In cases that all
four replicates yielded empty spectra (e.g., S58) or
showed poor QC values (indicated with circled sample
codes in Figure 4) the sample was excluded from
further analysis. Applying the selection of one high
quality spectrum for each sample ensures standardized
further statistics, whereas upon considering all replicate
spots the final profile is obtained after averaging of two,
three or four spectra.
Another way to evaluate the similarity of multiple
MALDI profiles is using the dot-product similarity to a
reference spectrum as proposed by Yergey and cowork-
ers [35]. In such a comparison, all signal is taken into
account, including background peaks. The quality of
spectra has been evaluated in detail counting the num-
ber of peaks in each replicate measurement [50]. Note
that the number of peaks in a spectrum may be high as
a result of contaminants and as such is earmarked
“good quality”. The same problem will arise upon
using total ion intensities, which is exemplified in
Figure 5. Here, the FTICR spectrum of no. 3 contains
mostly polymers with high signal-to-noise ratios and
will result in a false positive. As an alternative, peak
picking algorithms are widely used to determine inten-
sities of specific compounds in a spectrum. In combina-
tion with peak picking the quality of one single isotope
distribution can be determined using the “sophisticated
numerical annotation procedure” or SNAP (Bruker).
When summarizing the SNAP quality factors of the five
selected peptides, a similar trend as in our proposed
quality values was observed. However, the extraction of
SNAP quality factors from large numbers of mass
spectra is time-consuming due to necessary peak pick-
ing and deconvolution of each spectrum. Moreover, in
the case of a low quality spectrum these processes are
often not robust and make automation more difficult.
When manually applying SNAP on the same five
peptides used for alignment, out of the four replicates
in Figure 4, the same profiles were selected as low
quality.
Comparative Analysis of MALDI-TOF and
MALDI-FTICR Spectra
For the purpose of comparing TOF and FTICR serum
peptide profiles, the same 192 spots on a MALDI target
plate were measured both on a MALDI-TOF and a
MALDI-FTICR instrument. The QC value for each TOF
spectrum as well as for each FTICR spectrum was
determined according to eq 1. The results are plotted in
Figure 5 after sorting. Here, it can be observed that a
small fraction of the spectra showed a drastically in-
creased QC value that is indicative for a poor spectral
quality. It was verified that all TOF-spectra of MALDI-
spots with high QC value also yielded low quality
FTICR-spectra. In other words, trend analysis of bothTa Th (s
e
pe P
e m
14 17 18 26 29 *P
e
83 in
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low quality data. It is important to note that the choice
Figure 4. (a) Histogram of 384 QC values of 9
with MALDI-TOF. The low values (short bars) in
automatically assigned when an empty spectrum
that from the total batch of recorded peptide pro
data were not suitable for further analysis. The cu
seven samples, all four replicates yielded a poo
sample code). As a result, when taking into acc
each sample, 93% of the data were of high quality
of four replicate MALDI-TOF spectra of sample
each of these peptide profiles allowed the selec
according to the QC method resulted in sample
according to the sum of SNAP quality factors of
the first spectrum) resulted for samples 23 andof a cut-off point in Figure 5 will be different for eachMALDI target plate considered. Any chosen cut-off
point for the discrimination between the high and the
an serum samples measured in quadruplicate
te high quality spectra while a negative value is
corded. Based on these QC values it was found
63 spectra were of poor quality, i.e., 16% of the
point is indicated with an arrow in the plot. For
lity spectrum (indicated with a circle over the
only the spectrum with the highest quality for
included for further analysis. (b) Two examples
and S83. The calculation of the QC values for
of one spectrum for further analysis. Ordering
n 4-1-2-3 and in sample 83 in 4-2-3-1. Ordering
ame five peptides (indicated with an asterisk in
1-2-4-3 and 2-4-3-1, respectively.6 hum
dica
is re
files,
t-off
r qua
ount
and
s S21
tion
23 i
the spoor quality spectra based on QC values will introduce
1523J Am Soc Mass Spectrom 2010, 21, 1515–1525 QUALITY CONTROL BASED ON ISOTOPIC DISTRIBUTIONS FOR PROFILINGfalse-positive and false-negative results. For a quantita-
tive analysis, the normalized intensities estimated from
the polyaveragine peptides, the average ratios of the
isotopic distributions and their coefficients of variation
were evaluated for the five peptides discussed earlier
(see Figure 2) and the results are summarized in Table
1. In this evaluation, the 50 MALDI-TOF and the 50
MALDI-FTICR mass spectra with lowest QC values
were selected from the results obtained from 192 pep-
tide profiles in Figure 5. It can be seen from Table 1 that
the observed isotope ratios were in good agreement
with those estimated from the polyaveragine distribu-
tion. For example, the averaged isotope ratio of the first
and the second peak in the distribution of the peptide at
m/z 1865 was 1.1 in the TOF spectra and 1.0 in the
FTICR, which is in good agreement with the estimated
value of 1.0 from the polyaveragine peptide with m/z
1886. The results in Table 1 show that the coefficients of
variation of the first isotope ratios were within 6% and
13% for MALDI-TOF and MALDI-FTICR, respectively.
With respect to the possibility of overlap of multiple
peptides, it was observed fromMALDI-FTICR data that
them/z regions of the five peptides manually selected for
the QC method contained a singly species. Finally, if
in the serum, glycopeptides would be present in which
the contribution of the glycan part is relatively large,
these would be lost upon the RPC18 extraction. This
leaves inherent deviations from the polyaveragine pep-
tide as the only explanation for different isotopic distri-
butions in the five peptides. Thus, the observed devia-
tions can be attributed to the differences between the
real and the estimated composition.
Conclusions
In this study, the isotopic distributions of a small set of
Figure 5. Plot of QC values derived from 1
peptide profiles. These 192 profiles were obtaine
on a MALDI target plate. The QC values are cal
five peptides selected in Figure 2. After sorting
trends in peptide profile quality are observed.peptides were used as a quality control parameter forthe evaluation of MALDI-TOF and MALDI-FTICR
spectra. This novel QC method allows a semi-
automated selection of a good spectrum from repli-
cate measurements of one sample and for the removal
of low quality spectra from further statistical analy-
sis, which is necessary for large-scale study. The
isotopic distributions of five peptides (present in all
serum samples) were determined and evaluated in
both high-resolution MALDI-TOF and ultrahigh res-
olution MALDI-FTICR spectra. The selected isotope
patterns were compared with polyaveragine distribu-
tions to calculate a quality control value for each
single mass spectrum. Sorting the obtained QC values
allowed the selection of the best MALDI spectrum
from replicate spots and the removal of low quality
spectra from further data analysis. Examples of odd
peptide isotope distributions in MALDI-TOF spectra
could be rationalized from corresponding ultrahigh
resolution FTICR profiles that showed overlap of
different peptides. As was earlier shown and has
been discussed by other groups, multiple factors can
invalidate the results of peptide profiling studies. To
obtain a confident result, the full workflow of a
profiling study should be highly standardized. The
novel QC parameter used in this study is objective
and facilitates further data analysis in large scale
clinical studies. The proposed QC value can be deter-
mined for any isotopically-resolved MALDI-profile,
i.e., this method is independent of the type of instru-
ment, the manufacturer, or the software used for data
processing. The use of this parameter in combination
with other quality criteria that take into account
signal-to-noise, reproducibility, and baseline thresh-
old should result in a better selection of high-quality
spectra. The integration of all such metrics for qua-
lity evaluation into one single method is under
ALDI-TOF and MALDI-FTICR human serum
m 96 different samples after duplicate spotting
ed applying eq 1 to the isotopic distributions of
ALDI spot numbers by their QC values, clear92 M
d fro
culat
the Mdevelopment.
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